GlassScriptPhysician profile
Susan H Strich
NPI 1326026501
$1,050.21
in general payments reported to CMS, 2019-2025
19 companies · $557 in 2025
The $557 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.22 · 2021: $45.57 · 2022: $48.00 · 2023: $14.40 · 2024: $336 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $907.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $171.20 | 2024-2025 | Airsupra, Nexium, Farxiga |
| Amgen INC. | $143.61 | 2024-2025 | Evenity, Prolia, Otezla |
| Janssen Pharmaceuticals, INC | $107.97 | 2021-2023 | Xarelto |
| Abbvie INC. | $107.58 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $90.26 | 2025 | Caplyta |
| Pfizer INC. | $75.79 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $73.31 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $44.81 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Corcept Therapeutics | $37.67 | 2025 | Korlym |
| Lilly USA, LLC | $32.35 | 2024-2025 | Zepbound, Mounjaro |
| Exact Sciences Corporation | $24.98 | 2024 | Cologuard Collection Kit |
| Regeneron Healthcare Solutions, INC. | $21.19 | 2025 | Dupixent |
| Lundbeck LLC | $21.02 | 2024 | Rexulti |
| Axsome Therapeutics, INC. | $20.69 | 2025 | Auvelity |
| Abiomed | $16.85 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $16.70 | 2024 | Camzyos |
| Puma Biotechnology, INC. | $16.06 | 2025 | |
| Glaxosmithkline, LLC. | $15.04 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.13 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Strich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.